Mangalam Drugs & Organics Ltd. stock analysis
Want to see IN:MANGALAM full AI Analyst Report?
Mangalam Drugs & Organics Ltd. (MANGALAM) Stock Price & Analysis
MANGALAM Stock Chart & Stats
- Day’s Range
- INR 28.28 - INR 28.75
- 52-Week Range
- INR 22.70 - INR 58.78
- Previous Close
- INR 29.63
- Volume
- 15.57K
- Average Volume (3M)
- 2,411
- Market Cap
- INR 468.99M
- Enterprise Value
- INR 1.38B
- Total Cash (Recent Filing)
- INR 8.35M
- Total Debt (Recent Filing)
- INR 903.89M
- Price to Earnings (P/E)
- ―
- Beta
- 0.56
- Next Earnings
- Feb 14, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Dec 21, 2017
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Specialty Intermediate Business
The company serves pharmaceutical and broader chemical value chains with specialized intermediates rather than undifferentiated consumer products. This industrial positioning can support recurring demand across multiple applications and provides a platform for higher-value downstream derivatives over the medium term.
Positive Equity Base And Asset Scale
Positive net worth and a sizable asset base provide an operating foundation despite the recent downturn. These resources can support continued manufacturing activity and give management more flexibility than a balance sheet with negative equity, provided leverage and profitability stabilize.
Demonstrated Profitability And Cash Generation
Historical profitability and periods of solid operating cash generation show that the business has previously converted its operations into earnings and cash. This evidence supports the possibility of recovery if demand, product mix, utilization, and operating efficiency improve from current levels.
Bears Say
Sharp Profitability Deterioration
The move from modest FY2025 profitability to a substantial FY2026 loss indicates that earnings are currently highly vulnerable to operating conditions. Negative operating margins reduce internal funding capacity and make a durable recovery dependent on restoring profitable production and sales.
Revenue Contraction
A multi-year pattern of declining revenue suggests more than a single-period earnings disruption and raises concern about demand, volumes, pricing, or product mix. Continued contraction would weaken fixed-cost absorption, restrict investment capacity, and make margin recovery harder to sustain.
Weak Cash Generation And Higher Leverage
Negative operating and free cash flow leave less internally generated funding for operations, investment, and debt service. Combined with materially higher leverage, this increases financial pressure and reduces flexibility if weak profitability or cash conversion persists over the next several quarters.
Mangalam Drugs & Organics Ltd. News
MANGALAM FAQ
What was Mangalam Drugs & Organics Ltd.’s price range in the past 12 months?
What is Mangalam Drugs & Organics Ltd.’s market cap?
When is Mangalam Drugs & Organics Ltd.’s upcoming earnings report date?
How were Mangalam Drugs & Organics Ltd.’s earnings last quarter?
Is Mangalam Drugs & Organics Ltd. overvalued?
Does Mangalam Drugs & Organics Ltd. pay dividends?
What is Mangalam Drugs & Organics Ltd.’s EPS estimate?
How many shares outstanding does Mangalam Drugs & Organics Ltd. have?
What happened to Mangalam Drugs & Organics Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Mangalam Drugs & Organics Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Mangalam Drugs & Organics Ltd.
Based in Mumbai, India, Mangalam Drugs & Organics Limited, established in 1972, operates as a global pharmaceutical enterprise. The company is engaged in the production and distribution of a diverse range of medications, drugs, and associated pharmaceutical goods, serving both domestic Indian and international markets. Its offerings encompass various active pharmaceutical ingredients (APIs), chemical intermediates, specialized compounds, and impurities, which are crucial for treatments targeting conditions such as malaria, pain and inflammation, high blood pressure, and retroviral infections.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Govardhan Murlidhar Dhoot
- Employees
- 319
- Website
- www.mangalamdrugs.com
- Address
- Rupam Building, Mumbai, MA, 400 001, IN
Mangalam Drugs & Organics Ltd. (MANGALAM) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 4 | 15 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 0 | 0 | 12 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| IN:BIOFILCHEMBiofil Chemicals & Pharmaceuticals Ltd. | ||
| IN:LASALasa Supergenerics Ltd. | ||
| IN:PARPar Drugs and Chemicals Limited | ||
| IN:VAISHALIVaishali Pharma Ltd. | ||
| IN:VIVIMEDLABVivimed Labs Limited |









